INT177318

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2004
Last Reported 2008
Negated 2
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 3.39
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (NR1H4) signal transduction (NR1H4) nucleus (NR1H4)
Anatomy Link Frequency
colon 2
NR1H4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Kinase C 2 78.00 Quite High
agonist 76 76.48 Quite High
Inflammation 26 5.00 Very Low Very Low Very Low
cINOD 6 5.00 Very Low Very Low Very Low
COX-2 inhibitor 4 5.00 Very Low Very Low Very Low
withdrawal 4 5.00 Very Low Very Low Very Low
imagery 4 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
Inflammatory response 2 5.00 Very Low Very Low Very Low
Paracetamol 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Endometriosis (extended) 2 99.56 Very High Very High Very High
Apoptosis 28 98.84 Very High Very High Very High
Breast Cancer 46 98.80 Very High Very High Very High
Colon Cancer 90 98.08 Very High Very High Very High
Lung Cancer 14 97.36 Very High Very High Very High
Cancer 244 90.40 High High
Hematologic Neoplasms 4 76.48 Quite High
Malignant Neoplastic Disease 22 74.44 Quite High
Disease 62 71.44 Quite High
Immunotherapy Of Cancer 6 70.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The

combination of RXR ligand with ciglitazone also cooperatively inhibits the

Negative_regulation (inhibits) of RXR Binding (combination) of
1) Confidence 0.14 Published 2008 Journal PPAR Research Section Body Doc Link PMC2408709 Disease Relevance 1.36 Pain Relevance 0.04
/RXR heterodimer by their respective ligands synergistically inhibits cell growth, while inducing apoptosis in human colon cancer cells when the phosphorylation of RXR?
Negative_regulation (inhibits) of RXR Binding (heterodimer) of in colon associated with colon cancer and apoptosis
2) Confidence 0.14 Published 2008 Journal PPAR Research Section Abstract Doc Link PMC2408709 Disease Relevance 0.51 Pain Relevance 0
Altogether, impaired interaction with RXR?
Negative_regulation (impaired) of RXR Neg (impaired) Binding (interaction) of
3) Confidence 0.04 Published 2004 Journal Nucl Recept Section Body Doc Link PMC406421 Disease Relevance 0 Pain Relevance 0.04
Thus we suspect that impaired heterodimerization with RXR?
Negative_regulation (impaired) of RXR Neg (impaired) Binding (heterodimerization) of
4) Confidence 0.03 Published 2004 Journal Nucl Recept Section Body Doc Link PMC406421 Disease Relevance 0 Pain Relevance 0
PPAR/RXR heterodimers can competitively inhibit ER binding at specific estrogen
Negative_regulation (/) of RXR Binding (heterodimers) of
5) Confidence 0.02 Published 2008 Journal PPAR Research Section Body Doc Link PMC2605846 Disease Relevance 0.73 Pain Relevance 0
PPAR/RXR heterodimers can competitively inhibit ER binding at specific estrogen
Negative_regulation (inhibit) of RXR Binding (heterodimers) of
6) Confidence 0.02 Published 2008 Journal PPAR Research Section Body Doc Link PMC2605846 Disease Relevance 0.79 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox